{"id":"2b73db3c-839f-4443-86b4-e1bb8609d3be","name":"CorTec","slug":"cortec","description":"CorTec is a Freiburg-based clinical-stage neurotechnology company developing the [Brain Interchange](/models/cortec-brain-interchange) BCI system, a fully implantable bidirectional brain-computer interface for stroke motor rehabilitation. First and only European company with an FDA-approved BCI clinical trial. FDA Breakthrough Device Designation and TAP Program acceptance (April 2026). Three patients implanted at Harborview Medical Center, Seattle. 500+ days of continuous stable operation demonstrated.","status":null,"founded":2010,"hq":"Freiburg, Germany","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"https://www.cortec-neuro.com","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[],"keyFacts":[],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:26:47.782Z","updatedAt":"2026-08-08T22:51:44.288Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/cortec","url":"https://registry.deploy.report/companies/cortec","name":"CorTec","description":"CorTec is a Freiburg-based clinical-stage neurotechnology company developing the [Brain Interchange](/models/cortec-brain-interchange) BCI system, a fully implantable bidirectional brain-computer interface for stroke motor rehabilitation. First and only European company with an FDA-approved BCI clinical trial. FDA Breakthrough Device Designation and TAP Program acceptance (April 2026). Three patients implanted at Harborview Medical Center, Seattle. 500+ days of continuous stable operation demonstrated.","identifier":"2b73db3c-839f-4443-86b4-e1bb8609d3be","foundingDate":"2010","address":"Freiburg, Germany","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"claimed-not-verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":0,"primary_source_types":[]}}}